The Latest Cardiac and Vascular News
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct […]
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status – SAN FRANCISCO, March 04, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of […]
– Two Bodies of Research Led by Philippe Généreux, MD and Colleagues were Presented Today at 2023 ACC Annual Meeting – – Key Findings Demonstrate Increased Mortality Across All Degrees of Severity of Aortic Stenosis, Suggesting the Need to Re-Evaluate Currently Recommended Timing of Intervention, and Highlight the Importance of the Extent […]
GUARDIAN Registry data presented at ACC 2023 has shown use of the Paragonix SherpaPak® Cardiac Transport System was associated with improved outcomes as compared to the use of traditional cold storage in LVAD patients undergoing Heart Transplantation.1 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc., a leading organ transplant company, announces new research from […]
MK-0616 was generally well tolerated and reduced LDL-C across all dose levels compared to placebo Merck plans to start Phase 3 pivotal study in the second half of 2023 RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase […]
The publication highlights the effectiveness of the device based on the combination of hemocompatibility and autoregulation PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, […]
BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2022. “Our Simoa technology continues to be on the forefront of research, testing, therapeutic trials and has been an integral part of […]
Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and triage patients suspected with HCM SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, […]
Future Hub presentation to be accompanied by updated results from Vista.ai cardiac MRI study conducted at Brigham and Women’s Hospital NEW ORLEANS, March 3, 2023 /PRNewswire/ — Vista.ai, a pioneer and leader in automated MRI solutions, today announced that Dr. Michael Salerno, Chief, Cardiovascular Imaging at Stanford Health Care, will conduct a live remote cardiac […]
DUBLIN, March 2, 2023 /PRNewswire/ — The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 2, 2023, approved the fiscal year 2023 fourth quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May […]
